The independent platform for news, articles and advice for professionals in laboratory medicine

Lonza launches new cell culture medium for therapy development

Lonza has launched the new TheraPEAK T-VIVO cell culture medium, a novel chemically defined medium developed to optimise CAR T-cell manufacture.

Free from animal-origin components, the medium improves consistency and process control, and simplifies regulatory approval for faster time-to-market.

The manufacture of CAR T cells has traditionally relied on the use of animal or human serum, which is highly variable and may contain adventitious agents. Serum therefore requires stringent safety testing, screening, and stockpiling of suitable-quality batches, making for a more costly and time-consuming manufacturing process.

Companies using the new medium can achieve the required level of performance without needing to add human serum (HS) or components – a problem encountered with many earlier serum-free media. This launch is the latest step in Lonza’s journey to expedite cell therapy commercialication for its customers.

Lonza’s new GMP-grade medium is chemically defined and uses only recombinant proteins. By providing greater batch-to-batch consistency and supply security, it can accelerate pre-clinical development, regulatory approval, and therapy production. The medium also provides minimal contamination risk and a reduced traceability and documentation burden.

Lonza will present a talk with the Fraunhofer Institute for Cell Therapy and Immunology (IZI), which tested the new medium as part of a laboratory-based CAR T-cell manufacturing process, at the American Society of Cell & Gene Therapy (ASGCT) conference. The talk will take place at 15:45 on 18 May 2023, in the Exhibit Hall Presentation Theater at Los Angeles Convention Center.

Erin Brooks, Senior Global Product Manager, Bioscience, Lonza, commented: “Through this launch, we are enabling unprecedented control over raw materials and manufacturing processes, and unlocking greater end-product consistency for customers. With fewer barriers to a faster, more cost-efficient route to market, manufacturers can now focus on what matters: transforming patients’ lives for the better.”

The TheraPEAK T-VIVO medium is available to cell therapy manufacturers globally.

 

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Upcoming Events

UKMedLab23

Royal Armouries, Leeds
12-14 June 2023

Liverpool Pathology 2023

University of Liverpool
27-29 June

Microscience Microscopy Congress 2023 (mmc 2023, incorporating EMAG 2023)

Manchester Central Conference Centre
4-6 July 2023

Annual SHOT Symposium 2023

Etihad Stadium, Manchester, M11 3FF
4 July 2023

SHOT webinar: Positive patient identification for safe transfusions in adults

Online
11 July

SHOT webinar: Accurate and complete patient identification for safe transfusions in children

Online
19 July

Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.

Download the FREE Pathology In Practice app from your device's App store

Step Communications Ltd, Step House, North Farm Road, Tunbridge Wells, Kent TN2 3DR
Tel: 01892 779999 Fax: 01892 616177
www.step-communications.com
© 2023 Step Communications Ltd. Registered in England. Registration Number 3893025